Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › fosaprepitant

fosaprepitant

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of fosaprepitant

7 trials tracked of fosaprepitant: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 24 citations.

7Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 4 Other / NA 1
  1. Phase 3 A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC Completed · 24 cited
  2. Phase 4 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed
  3. Phase 2 Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy Completed
  4. Phase 2 Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Completed
  5. Phase 2 Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) Completed
  6. Phase 2 Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors Completed
Show 1 more trials
  1. N/A Fosaprepitant in Patients Receiving Ifosfamide-based Regimen Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Focinvez (fosaprepitant) for Prevention of Chemotherapy-Induced Nausea and Vomiting
Oncology FDA Approval
FDA Approves Focinvez (fosaprepitant) for Prevention of Chemotherapy-Induced Nausea and Vomiting FDA approves a new intravenous drug to help prevent nausea and vomiting from chemotherapy
The FDA has approved Focinvez, a substance P/NK1 receptor antagonist, for the prevention of acute and delayed nausea and vomiting associated…
FDA approves new IV drug to prevent severe nausea and vomiting from chemotherapy in adults and children 6 months and older.
FDA Apr 2, 2026